Skip to main content
NCBI home page
Gut logoLink to Gut
. 1994 Sep;35(9):1282–1286. doi: 10.1136/gut.35.9.1282

Optimum dose of olsalazine for maintaining remission in ulcerative colitis.

S P Travis 1, C Tysk 1, H J de Silva 1, H Sandberg-Gertzén 1, D P Jewell 1, G Järnerot 1
PMCID: PMC1375708  PMID: 7959238

Abstract

To evaluate the optimum dose of olsalazine for maintaining remission in ulcerative colitis, 198 patients in remission for more than three months were randomly assigned to receive 0.5 g, 1.0 g, or 2.0 g/day for 12 months. A dose-ranging effect was detected in the per protocol analysis, with remission rates of 60% (0.5 g), 70% (1.0 g), and 78% (2.0 g) (p = 0.03, trend in proportions). The higher dose was most effective in patients with proctitis (90% remission on 2 g/day, p = 0.03) or those in remission for less than 12 months before the trial (88% remission on 2 g/day, p = 0.0006). There was little dose-ranging effect in patients with extensive colitis or those in remission for more than 12 months. Diarrhoea necessitated treatment withdrawal in 12%. The optimal dose of olsalazine for maintaining remission in ulcerative colitis is 1 g/day. For patients with proctitis or recent relapse, 2 g/day may be preferable, although the dose seems to be less important in patients with more extensive disease or those in long term remission.

Full text

PDF
1282

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azad Khan A. K., Howes D. T., Piris J., Truelove S. C. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut. 1980 Mar;21(3):232–240. doi: 10.1136/gut.21.3.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. DICK A. P., GRAYSON M. J., CARPENTER R. G., PETRIE A. CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS. Gut. 1964 Oct;5:437–442. doi: 10.1136/gut.5.5.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Das K. M., Eastwood M. A., McManus J. P., Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973 Sep 6;289(10):491–495. doi: 10.1056/NEJM197309062891001. [DOI] [PubMed] [Google Scholar]
  4. De Vos M., Verdievel H., Schoonjans R., Praet M., Bogaert M., Barbier F. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut. 1992 Oct;33(10):1338–1342. doi: 10.1136/gut.33.10.1338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Giaffer M. H., Holdsworth C. D., Lennard-Jones J. E., Rodrigues C. A., McIntyre P. B., Manjunatha S., Baron J. H., Barrison I. G., Polson R. J., Hoare A. M. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment Pharmacol Ther. 1992 Aug;6(4):479–485. doi: 10.1111/j.1365-2036.1992.tb00561.x. [DOI] [PubMed] [Google Scholar]
  6. Ireland A., Jewell D. P. Mechanism of action of 5-aminosalicylic acid and its derivatives. Clin Sci (Lond) 1990 Feb;78(2):119–125. doi: 10.1042/cs0780119. [DOI] [PubMed] [Google Scholar]
  7. Ireland A., Mason C. H., Jewell D. P. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut. 1988 Jun;29(6):835–837. doi: 10.1136/gut.29.6.835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Järnerot G. Clinical tolerance of olsalazine. Scand J Gastroenterol Suppl. 1988;148:21–23. doi: 10.3109/00365528809101542. [DOI] [PubMed] [Google Scholar]
  9. Kiilerich S., Ladefoged K., Rannem T., Ranløv P. J. Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group. Gut. 1992 Feb;33(2):252–255. doi: 10.1136/gut.33.2.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Meyers S., Sachar D. B., Present D. H., Janowitz H. D. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology. 1987 Dec;93(6):1255–1262. doi: 10.1016/0016-5085(87)90253-8. [DOI] [PubMed] [Google Scholar]
  11. Mohsen A. Q., Mulvey D., Priddle J. D., Parsons D. S., Jewell D. P. Effects of olsalazine in the jejunum of the rat. Gut. 1987 Mar;28(3):346–352. doi: 10.1136/gut.28.3.346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pamukcu R., Hanauer S. B., Chang E. B. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid. Gastroenterology. 1988 Oct;95(4):975–981. doi: 10.1016/0016-5085(88)90172-2. [DOI] [PubMed] [Google Scholar]
  13. Raimundo A. H., Patil D. H., Frost P. G., Silk D. B. Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects. Gut. 1991 Mar;32(3):270–274. doi: 10.1136/gut.32.3.270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rao S. S., Holdsworth C. D., Read N. W. Symptoms and stool patterns in patients with ulcerative colitis. Gut. 1988 Mar;29(3):342–345. doi: 10.1136/gut.29.3.342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Riley S. A., Mani V., Goodman M. J., Dutt S., Herd M. E. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991 Feb;32(2):174–178. doi: 10.1136/gut.32.2.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Riley S. A., Mani V., Goodman M. J., Lucas S. Why do patients with ulcerative colitis relapse? Gut. 1990 Feb;31(2):179–183. doi: 10.1136/gut.31.2.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sandberg-Gertzén H., Järnerot G., Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology. 1986 Apr;90(4):1024–1030. doi: 10.1016/0016-5085(86)90882-6. [DOI] [PubMed] [Google Scholar]
  18. Truelove S. C. Evolution of olsalazine. Scand J Gastroenterol Suppl. 1988;148:3–6. doi: 10.3109/00365528809101538. [DOI] [PubMed] [Google Scholar]
  19. Wadworth A. N., Fitton A. Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs. 1991 Apr;41(4):647–664. doi: 10.2165/00003495-199141040-00009. [DOI] [PubMed] [Google Scholar]
  20. Willoughby C. P., Aronson J. K., Agback H., Bodin N. O., Truelove S. C. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut. 1982 Dec;23(12):1081–1087. doi: 10.1136/gut.23.12.1081. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES